Respiratory Syncytial Virus (RSV) is a virus commonly caused by viral (LRI) lower respiratory tract illness, especially in children and infants. If prevalent in the body, the disorder progresses significantly in the elderly population and immunocompromised patients as well. The vaccines available today for the said disorder prevent its progression in the body. People at most risk of the said disorder include the infants and the elderly individuals. The most recently improved vaccine for respiratory syncytial virus is DS-Cav1 is the most promising vaccine. The patient recovers better by better fighting of RSV neutralizing antibodies in the body. Moreover, extensive research is being done for the development of new vaccines for RSV.
Major Key Players of the Respiratory Syncytial Virus (RSV) Vaccines Market are:
GlaxoSmithKline, Novavax, Johnson & Johnson’s Janssen, AstraZeneca’s MedImmune and Bavarian Nordic
GlaxoSmithKline, Novavax, Johnson & Johnson’s Janssen, AstraZeneca’s MedImmune and Bavarian Nordic
No comments:
Post a Comment